{
  "docId": "019dd923-622c-750b-8b9d-167a31878e2a",
  "docSlug": "beab175aaed8",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": null,
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 24,
  "pageCount": 197,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Uses a timeline visualization to highlight the gap between historical performance (3 launches in 15 years) and projected performance (10 launches in 8 years).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9d-167a31878e2a/24",
  "deckHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "callout",
      "text": "Assuming Celgene’s near-term launch products can generate $10.8 billion revenue by 2028, another 5, on average, blockbuster products would be needed to reach Bristol-Myers’ 2028 revenue base case. This means that Bristol-Myers is assuming that Celgene can produce, on average, 10 blockbuster drugs in 8 years...after only producing 3 in the last 15 years! Why should shareholders underwrite such aggressive assumptions and take on so much risk??",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "def2a03f-8469-4098-b97d-77221a71e597",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Timeline showing 2005 (Revlimid), 2013 (Pomalyst), 2014 (Otezla) vs 2020E-2028E projection.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adb44b79-2fbb-4f39-909d-c8fddba8ba5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "In its base case, Bristol-Myers is assuming Celgene can generate blockbuster drugs at a pace completely out-of-line with historical performance, adding substantial risk to the deal.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9464923e-9144-423c-8467-e24e74bfa81a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Public company filings, Bristol-Myers investor relations, Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "828242c0-40c4-45b2-bc0d-e06368851fc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "title",
      "text": "Bristol-Myers needs Celgene’s pipeline to churn out blockbusters at an unprecedented rate",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "420c5031-be31-43d9-ab5b-ce3d17d84956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Celgene Has Only Developed 3 Blockbusters In 15 Years, But Bristol-Myers’ Base Case Assumes, On Average, 10 Blockbusters in the Next 8 Years",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b54dbaea-cf8f-44e1-b918-4df38369a60f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "192f85c8-dac6-4d1e-abe2-aa0673e15787",
      "evidence": "Contrasts historical performance with future projections to undermine deal thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "1be2f377-bde5-4e96-aa19-6d36bdad8e4b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problems, providing more details on the acquisition's flaws and potential risks.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "51fbe075-66b5-4a33-8803-f580c7273c18",
      "evidence": "The presentation highlights the potential costs of inaction, implying that shareholders would be better off if the deal is not completed.",
      "position": 0,
      "objective": "What are the costs of not addressing the issues with the acquisition?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}